Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Japan's Health Ministry"


4 mentions found


Read previewIn Japan, cases of an uncommon but deadly bacterial infection have spiked in recent months, concerning health officials, the Washington Post reported. At least 77 deaths have been reported due to these STSS infections, with most fatal cases occurring in people over 50. Since the coronavirus pandemic, health officials worldwide have expressed concern about increasing bacterial and viral infection rates. In 2022, UK health officials reported 19 child deaths due to group-A streptococcal infections, the same bacteria that causes STSS. Vaccines could help prevent the spread of these rare but potentially deadly bacterial infections, health experts said.
Persons: , Steer, we've, Andrew Steer Organizations: Service, Washington Post, Japan's Health Ministry, Business, CDC, Murdoch Children's Research Locations: Japan, Melbourne, Australia
Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. But Jim Cramer said Thursday that he expects yields to peak soon, which should bolster the stock market. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Jim, Stanley Black, Decker, Mizuho, Jim Cramer's Organizations: CNBC, Treasury, Procter & Gamble, Broadcom, GE HealthCare Mizuho, GE HealthCare, Mizuho, Costco, TJX, Club, Costco Wholesale
TOKYO (AP) — Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population. Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration. Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures. Eisai is committed to delivering Leqembi to people who need it and their families “as a new treatment,” said Haruo Naito, the company’s CEO.
Persons: Fumio Kishida, Kishida, Eisai, Leqembi, , Haruo Naito Organizations: TOKYO, Biogen Inc, U.S . Food, Drug Administration, Kyodo Locations: Japan
For more than two years, overseas travelers have had to quarantine upon arrival in China because of Covid restrictions. The U.S. government is considering imposing new Covid rules for travelers from China, officials said, citing concerns over virus-related data released by the Chinese government. The officials pointed to Japan's recent measures which require a negative Covid test for travelers arriving from mainland China from Dec. 30 – as China faces a sharp surge in infections nationwide following an abrupt reopening. Travelers from China without a valid vaccination certificate will also be required to take a pre-departure test, the notice from Japan's health ministry added. The measures will not apply to those traveling from Hong Kong and Macao, according to the notice.
Total: 4